Polyethylene glycol interferon-α2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia

被引：0

作者：

Cervantes, F

Camós, M

Boqué, C

Besses, C

Alcalá, E

Sureda, A

机构：

[1] Hosp Clin Barcelona, Dept Hematol, E-08036 Barcelona, Spain

[2] IDIBAPS, Barcelona, Spain

[3] Hosp Neustra Senora Mar, Barcelona, Spain

[4] Hosp Sant Pau, Barcelona, Spain

[5] Hosp Especialidades Ctr Med La Raza, Jaen, Spain

来源：

HAEMATOLOGICA | 2004年 / 89卷 / 07期

关键词：

chronic myeloid leukemia; treatment; PEG-interferon; Ara-C;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：870 / 871

页数：2

相关论文

共 7 条

[1]

Baccarani M, 2003, BLOOD, V102, p183A

[2] Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon alpha-2b and low-dose cytosine arabinoside [J].

Garcia-Manero, G ;

Talpaz, M ;

Giles, FJ ;

Cortes, J ;

Faderl, S ;

O'Brien, S ;

Thomas, D ;

Verstovsek, S ;

Rios, MB ;

Shan, J ;

Ferrajoli, A ;

Wierda, W ;

Kantarjian, HM .

CANCER, 2003, 97 (12) :3010-3016

[3] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[4] Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study [J].

Michallet, M ;

Maloisel, F ;

Delain, M ;

Hellmann, A ;

Rosas, A ;

Silver, RT ;

Tendler, C .

LEUKEMIA, 2004, 18 (02) :309-315

[5] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

[6]

OBRIEN SG, 7 M EUR HEM ASS FLOR

[7] Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia [J].

Talpaz, M ;

O'Brien, S ;

Rose, E ;

Gupta, S ;

Shan, JQ ;

Cortes, J ;

Giles, FJ ;

Faderl, S ;

Kantarjian, HM .

BLOOD, 2001, 98 (06) :1708-1713